65,437 trials
Breast Cancer
Primary: Safety as Assessed by Number of Participants Experiencing Toxicity — 20; 0; 0 Participants
Congestion, Nasal
Primary: Change From Baseline in Mean Average Score of Nocturnal Rhinoconjunctivitis Quality of Life Questionnaire (NRQLQ) for Each Domain Problems (Sleep, Sleep Time, Symptoms…
Infertility
Primary: Ongoing Pregnancy Rate — 30.7; 31.6 Percentage of subjects
Chronic Rhinosinusitis · Endoscopic Sinus Surgery
Primary: Total Subjective Symptoms Visual Analog Scores (VAS) — 20.4; 20.7; 9.7; 8.9 score on a scale
Chronic Liver Disease · Thrombocytopenia
Primary: Percentage of Participants Who Required No Platelet Transfusion Prior to the Primary Invasive Procedure and No Rescue Therapy For Bleeding From Randomization Through 7…
Spinal Cord Injury · Bone Loss · Osteoporosis
Primary: Bone Mineral Density (BMD) of the Total Hip as Assessed by Dual-energy X-ray Absorptiometry (DXA) — 6.73; -0.34; 4.24 Percent change
Hyperhidrosis
Primary: Long-term Safety Assessed Through Adverse Events and Local Skin Reactions — 148; 153; 28; 120 Adverse Events and Local Skin Reactions
Nasolabial Folds · Marionette Lines · Wrinkles
Primary: Number of Subjects With Naturalness of Expression in Motion (2D Video) — 30 Participants
Non-alcoholic Fatty Liver Disease (NAFLD · Hypertriglyceridemia
Primary: Geometric Mean Ratio (Week 12/Baseline) of % Liver Fat as Assessed by MRI (Epanova Versus Placebo) — 0.98; 1.04 ratio of % liver fat — p=0.407
HIV-1 Infection · Tuberculosis
Primary: Percent of Participants With DMPA Concentrations Below 0.1 ng/mL at Week 12 — 11.9 percentage of participants
Barrett's Esophagus
Primary: Number of Subjects in Which the Targeted Locations Identified Through OFDI Imaging Correlates With the Biopsies. — 22 Participants
Rehabilitation
Primary: Number of VRP-Clinic Neck Movements That the Assessing Clinician Recognizes as Rehabilitation Movements — 320 Movements
Hemophilia A
Primary: Ease of Using Clotting Factor Treatment Score — 31.15 units on a scale — p=0.000
Hepatocellular Carcinoma (HCC)
Primary: Overall Survival (OS) — 13.6; 12.3 months
Glabellar Lines · Wrinkles
Primary: Proportion of Composite Responders Who Achieve at Least a 1-point Reduction From Baseline in Glabellar Line Severity Score (GLSS) at Maximum Frown. — 27; 26 Participants